Conclusion
The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bleyer WA, Krivit W, Chard RL, Hammond D (1979) Phase II study of VM26 in acute leukemia, neuroblastoma and other refractory childhood malignancies: A report from the Children's Cancer Study Group. Cancer Treat Rep 63:977–981
Bowman WP (1981) Childhood acute lymphocytic leukemia: progress and problems in treatment. Can Med Assoc J 124:129–142
Chessels JM, Cornbleet M (1979) Combination chemotherapy for bone marrow relapse in childhood lymphoblastic leukemia (ALL). Med Pediatr Oncol 6:359–365
Dombernowsky P, Nissen NI, Larsen V (1972) Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-o-2-thenylidene-β-D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 56:71–82
Ekert H, Ellis WM, Waters KD, Matthews RN (1979) Poor outlook for childhood acute lymphoblastic leukaemia with relapse. Med J Aust 2:224–226
Evans AE, Farber S, Brunet S, Mariano PJ (1963) Vincristine in the treatment of acute leukemia in children. Cancer 16:1302–1306
Karon M, Freireich EJ, Frei E, III, Taylor R, Wolman IJ, Djerassi I, Lee SL, Sawitsky A, Hananian J, Selawry O, James D, George P, Patterson RB, Burgert O, Haurani FI, Oberfield RA, Macy CT, Hoogstraten B, Blom J (1966) The role of vincristine in the treatment of childhood acute leukemia. Clin Pharmacol Ther 7:332–339
Krishan A, Paika K, Frei E, III (1975) Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM26, VP16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol 66:521–530
Mathé G, Schwarzenberg L, Pouillart P, Weiner R, Oldham R, Jasmin C, Rosenfeld C, Hayat M, Scheineder M, Annel JL, Ceoara B, Steresco-Nusset M, Vassal F et de (1974)_Essai de traitement de divers hematosacromes par le 4′-déméthyl-épipodophyllotoxine beta D thénylidène glucoside (VM26 or EPT). Nouv Presse Med 3:447–451
Rivera G, Avery T, Pratt C (1975) 4′-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-β-D-glucopyranoside) (NSC-122819; VM26) and 4′-demethylepipodophyllotoxin 9-(4,6-o-ethylidene-β-D-glucopyranoside) (NSC-141540; VP16-213) in childhood cancer: preliminary observations. Cancer Chemother Rep 59:743–749
Rivera G, Avery T, Roberts D (1975) Response of L1210 to combinations of cytosine arabinoside and VM26 or VP16-213. Eur J Cancer 11:639–647
Rivera G, Murphy SB, Aur RJA, Verzosa MS, Dahl GV, Mauer AM (1978) Recurrent childhood lymphocytic leukemia. Clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission. Cancer 42:2521–2528
Rivera G, Murphy SB, Wood A, Dahl GV, Bowman WP, Aur RJA (1979) Combination chemotherapy with prednisone, vincristine and the epipodophyllotoxin VM26 for refractory childhood lymphocytic leukemia (ALL). Blood (abstract) 54:265a
Rivera G, Aur RJ, Dahl GV, Pratt CB, Wood A, Avery T (1980) Combined VM26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia. Cancer 46:1284–1288
Rivera G, Dahl GV, Bowman WP, Avery TL, Wood A, Aur RJ (1980) VM26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia. Cancer 46:1727–1730
Rivera G, Dahl GV, Bowman WP, Aur RJA, Murphy SB, Tsiatis A (1981) Prolonged second marrow remission in children with lymphocytic leukemia (ALL) treated with VM26 and cytosine arabinoside (Ara-C). Proc AACR ASCO (abstract) 22:481
Stahelin H, Poschmann G (1978) Effects of the epipodophyllotoxin derivative VM26 in mitosis and in interphase. Oncology 35:217–219
Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky D (1967) Daunomycin, and antitumor antibiotic, in the treatment of neoplastic disease. Cancer 20:333–353
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rivera, G., Dahl, G.V., Murphy, S.B. et al. VM26 therapy in children with drug-refractory lymphocytic leukemia. Cancer Chemother. Pharmacol. 7, 169–172 (1982). https://doi.org/10.1007/BF00254541
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254541